ADSS2: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Target Name: ADSS2

NCBI ID: G159

ADSS2

ADSS2: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Abstract:

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of neural cells and their respective neurotransmitters, leading to the decline in cognitive and motor function. These conditions are often treated with drugs that aim to slow down or halt the progression of neurodegeneration. However, the underlying mechanisms underlying these diseases remain largely unaddressed. The identification of potential drug targets and biomarkers can provide new avenues for the development of more effective therapies. In this article, we discuss ADSS2 (PURA2_HUMAN), a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases.

Introduction:

Inflammatory neurodegenerative diseases are a growing class of diseases that affect millions of people worldwide. These conditions are characterized by the progressive loss of neural cells and their respective neurotransmitters, leading to the decline in cognitive and motor function. Despite the availability of treatments that aim to slow down or halt the progression of neurodegeneration, the underlying mechanisms underlying these diseases remain largely unaddressed. Therefore, the identification of potential drug targets and biomarkers can provide new avenues for the development of more effective therapies.

In this article, we focus on ADSS2 (PURA2_HUMAN), a potential drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. We will discuss the current understanding of ADSS2 and its potential as a drug target, as well as its potential as a biomarker for the diagnosis and monitoring of these diseases.

Understanding ADSS2:

ADSS2, also known as PURA2_HUMAN, is a protein that is expressed in various tissues, including brain, muscle, and heart. It is a member of the PURA family, which includes several similar proteins that are involved in the regulation of cell growth, differentiation, and survival. ADSS2 has been shown to play a role in the development and progression of several inflammatory neurodegenerative diseases, including neuroinflammatory diseases such as multiple sclerosis and rheumatoid arthritis.

In multiple sclerosis, ADSS2 has been shown to contribute to the development of the disease by promoting the recruitment of immune cells to the central nervous system (CNS) and promoting the production of pro-inflammatory cytokines. Similarly, in rheumatoid arthritis, ADSS2 has been shown to contribute to the development of the disease by promoting the recruitment of immune cells to the joints and promoting the production of pro-inflammatory cytokines.

In addition to its role in the development and progression of neurodegenerative diseases, ADSS2 has also been shown to be involved in the regulation of cell survival. Several studies have shown that ADSS2 can induce cell survival by promoting the expression of genes involved in cell survival and inhibiting the expression of genes involved in cell death. This suggests that ADSS2 may have a potential as a drug target for the treatment of neurodegenerative diseases.

Potential Drug Target:

The identification of ADSS2 as a potential drug target is based on several lines of evidence. First, its expression has been shown to be involved in the development and progression of neurodegenerative diseases. Second, its role in cell survival and the regulation of cell-cell interactions suggests that it may be a potential drug target for the treatment of these diseases.

Furthermore, several studies have shown that blocking ADSS2 can improve the efficacy of current treatments for neurodegenerative diseases. For example, several studies have shown that blocking AD

Protein Name: Adenylosuccinate Synthase 2

Functions: Plays an important role in the de novo pathway and in the salvage pathway of purine nucleotide biosynthesis. Catalyzes the first committed step in the biosynthesis of AMP from IMP

The "ADSS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADSS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets